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A class of small non-coding RNAs, the microRNAs (miRNAs), have recently attracted great attention in cancer
research since they play a central role in regulation of gene-expression and miRNA aberrant expression is found in
almost all types of human cancer. The discovery of circulating miRNAs in body fluids and the finding that they are
often tumor specific and can be detected early in tumorigenesis has soon led to the evaluation of their possible
use as cancer biomarkers and treatment-response predictors. The evidence that tumor cells communicate via the
secretion and delivery of miRNAs packed into tumor-released microvesicles has prompted to investigate miRNA
contribution as signaling molecules to the establishment and maintenance of the tumor microenvironment and the
metastatic niche in cancer. In this review we highlight the recent advances on the role of exosomal miRNAs as
mediators of cancer cell-to-cell communication.
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microRNAs (miRNAs) are a family of endogenous, non-
coding, tiny RNA molecules which modulate gene ex-
pression functioning both by targeting messenger RNA
degradation and suppressing protein translation. Thou-
sands of human protein-coding genes are regulated by
miRNAs, indicating that miRNAs are master regulators
of diverse biological systems, facilitating a rapid response
of body physiology. miRNAs have been shown to regu-
late every aspect of cellular activity, including differenti-
ation and development, metabolism, proliferation and
apoptosis. In addition, the biogenesis and function of
miRNAs are related to the molecular mechanisms of
various diseases including cancer. The intensive research
of the past years have demonstrated that miRNAs are
not only contained into cells, but are also detectable out-
side them, secreted in various body fluids (e.g. serum,
plasma, saliva, urine) routinely examined in patients
[1,2]. It is known that extracellular miRNAs are included
in small membranous vesicles or packaged with RNA-
binding proteins [3]. miRNAs contained into microvesi-
cles, and in particular into exosomes, have been shown
to function as secreted signaling molecules that
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unless otherwise stated.secreted exosomal miRNAs may reflect the molecular
changes of the cells from which they originate and can
therefore be seen as potential indicators for early recog-
nition of the onset of disease. In addition, since they are
relatively stable, disease-specific and can be efficiently
detected in body fluids and amplified by means of mo-
lecular biology tools such as real-time PCR, they can be
seen as ideal biomarkers in many pathological states in-
cluding cancer.
Thanks to their unique properties and functions,
miRNAs play a crucial role in human cancer develop-
ment and tumorigenesis as their expression is frequently
deregulated in many types of tumors, functioning either
as tumor suppressors or as oncogenes (oncomiRs). Fur-
thermore, miRNAs were shown to be responsible for
cancer-related inflammation, cancer drug resistance, and
regulation of cancer stem cells. Therefore, miRNAs have
generated great interest as a novel strategy in cancer
diagnosis and therapy [4].Exosomal miRNAs
The first observations that mature miRNAs are present
in cell-free blood plasma and serum was made in 2008
by several independent research groups [5-8]. Later, nu-
clease resistant extracellular miRNAs have been found
in all known biological fluids [9-12]. Since then, accu-
mulated reports have consistently shown that extracellu-
lar miRNAs can be shielded from RNAse degradationl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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apoptotic bodies, shedding vesicles and exosomes; or
(2) solely by complexing with AGO proteins [13-15].
Most miRNAs present in biological fluid have been
found MVs-free and associated with proteins of the
Ago family, which appear remarkably stable even in pro-
tease rich environment [16,17]. Some miRNA species
were also found in purified fractions of high-density lipo-
protein (HDL) from human plasma [18,19], although the
analyzed HDL-miRNAs constituted only a minor propor-
tion of the total circulating miRNAs. Circulating miRNAs
bound by Ago proteins are apparently non-specific rem-
nants resulting from physiological activity of the cells
and cell death [15,17]. On the contrary, extracellular
miRNAs included within MVs can be transferred to re-
cipient cells, alter gene expression and mediate func-
tional effects [20-25].
Exosomes
Exosomes are membrane vesicles of an average 30–
100 nm diameter, are formed within the multivesicular
bodies (MVBs), also known as late endosomes, and re-
leased upon fusion of MVBs with the plasma membrane
[26] from many different cell types in the body, such as
red blood cells, platelets, lymphocytes, dendritric cells,
and tumor cells. Exosome composition does not merely
reflect the cells of origin, but is enriched in specific pro-
teins, lipids and RNAs, indicating the existence of spe-
cialized sorting mechanisms, most of which are not fully
understood [27]. Exosome membranes are enriched in
cholesterol, sphingolipids, glycerophospholipids and cer-
amide [28], and bear both intraluminal and transmem-
brane proteins, with the same polarity as the plasma
membrane. Proteins enriched in exosomes include tetra-
spanins (CD63, CD81) and associated proteins such as
integrins, immunoglobulins and growth factor receptors;
cytoskeletal proteins (tubulin, actin); ESCRT-related pro-
teins (Alix, Tsg101); heat-shock proteins (hsp70, hsp90),
and proteins involved in vesicle trafficking such as Rab
GTPases, annexins and flotillin [29,30]. Exosomes are
also enriched in mRNAs and small RNA species, includ-
ing vaultRNA, tRNAs and miRNAs [31]. Recently,
tumor-derived exosomes have been shown to carry sin-
gle and double stranded DNA [32,33].
The profile of miRNAs in exosomes is specific, since
particular repertoires of miRNAs are selectively sorted,
while others are usually excluded. Moreover, profiling
studies have revealed that exosomes of different cel-
lular origin contain a unique expression profile of
mRNAs and miRNAs, which may also differ from the
signatures of their parent cells [24,34,35]. Hence,
exosome content reflects the nature and even the
state of the producer cell. A searchable compendium of
exosomal proteins and RNA is now accessible at ExoCarta(http://www.exocarta.org/). A recent study on exosomes
released from human colon carcinoma cells and purified
by immunocapture with different antibodies revealed two
different exosome populations distinct for both protein
and miRNA composition [36]. Interestingly, miRNA pas-
senger strands were particularly enriched in one exoso-
mal population, suggesting that miRNA biogenesis
may be interlinked with endosomal/exosomal process-
ing [36].
The exosome composition is crucial in determining
the outcome of the communication between donor and
recipient cells. The mechanism of exosome-mediated
cell-to-cell communication is particularly important in
cancer, since tumor cells constitutively secrete exosome,
which can target locally adjacent cells of the same type
(autocrine effect), neighboring cells of different types
(paracrine effect), or reach cells located at distant organs
after entering the blood stream (endocrine effect). These
exosomes play a key role in the modulation of the im-
mune response against the tumor [37-41], the induction
of angiogenesis [24,42], cell invasion and metastasis
[43,44]. Tumor cells are continuously subjected to a
range of stressors such as hypoxia, starvation or chemo-
therapeutic agents, and cancer progression depends on
the ability of cells to sense and adapt to these situations.
miRNA-based intercellular communication relies on
critical processes. First, miRNAs must be selectively and
actively secreted from cells and packaged into appropri-
ate carriers. Second, miRNAs must be protected from
circulating RNAses and transferred to targeted or
receptor-specific recipient cells. Finally and most im-
portantly, miRNAs must retain the ability to recognize
and repress mRNA targets in recipient cells [45].
miRNA sorting into exosomes
Exosome biogenesis [34,46], material cargo sorting
[46,47], and release [48] involve the endosomal sorting
complex required for transport (ESCRT complex), acting
together with associated proteins. The ESCRT complex
recognizes ubiquitinated membrane proteins and pro-
motes their internalization into the MVBs [49]. The lipid
content of exosomes appears also to play an important
role in both the packaging of exosomes and their deliv-
ery to downstream tissues. The tetraspanin family of
proteins, which appears specifically enriched in exo-
somes among extracellular vesicles, has a high affinity
for both sphingolipids and cholesterol, and brings along
these lipid molecules during exosome packaging [28,50].
The miRNA maturation process seems to be associated
to the formation and maturation of exosomes. Whether
packing of miRNAs into exosomes takes place at the
pre- or mature-miRNA level has to be yet fully under-
stood. Some authors reported that sequence motifs
present in mature miRNAs are able to control their
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nuclear ribonucleoprotein A2B1 (hnRNPA2B1) recogniz-
ing these motifs specifically binds exosomal miRNAs
and controls their loading into exosomes [51].
It has been suggested that sorting of pre-miRNAs into
exosomes could also be occurring in a sequence-
dependent manner and, indeed, pre-miRNA as well as
mature miRNAs are found in exosomes (Figure 1;
[52-55]). A very interesting work has recently revealed
that breast cancer exosomes, differently from normal
cell-derived exosomes, contain pre-miRNAs along with
the core RNA-induced silencing complex (RISC) pro-
teins, namely Dicer, Ago2 and TRBP, and display cell-
independent capacity to process pre-miRNAs into mature
miRNAs (Figure 1; [56]). In addition to miRNAs, exosomes
carry mRNAs [25], which also show a selective enrichment
[24]. Exosomes content in mRNAs seems to be enriched in
3’UTR fragments [18], and this might be important for the
sorting of specific mRNAs into these vesicles [57].
Recently, it has been shown that miRNA availability
for exosomal secretion is controlled, at least in part,
by the cellular levels of their targeted transcripts, imply-
ing that exosomal miRNA secretion is a mechanism
whereby cells rapidly dispose miRNAs in excess of their
targets to adjust miRNA:mRNA homeostasis [58]. While
these findings suggest that miRNA sorting may be a pas-
sive mechanism, increasing data indicate that exosomes
can be actively internalized by recipient cells, resulting
in miRNA transfer among cells of both homo- and het-
erotypic nature [21,24,25,59-61].Figure 1 Schematic representation of miRNA sorting into tumor cell-dExosomal miRNAs in cell-to-cell communication
The fact that exosomes are protected from the environ-
ment by their lipid bilayer makes them ideal delivery ve-
hicles for RNAs [62]. In fact, exosomal miRNAs are
more stable and resistant to degradation than cellular
miRNAs [63]. In addition, exosomes can deliver multiple
messages simultaneously, which make them an attractive
way of exchanging specific subsets of mRNA, miRNA,
or proteins between donor and recipient cells, also at a
distance.
The modality of interaction of exosomes with selected
target cells is still unclear. Both direct and indirect evi-
dences exist to suggest that EVs are internalized into re-
cipient cells, the first relying on the use of exosome
fluorescent labeling, the second based on the transfer of
functional miRNAs on target cells [64]. Exosomes dis-
play exquisite target cell selectivity in vitro and in vivo,
which is based, at least in part, on target cell ligand
interactions with exosomal tetraspanin-associated recep-
tors. Maintenance of internalization complexes and re-
use of these complexes for exosome uptake appear to be
a common theme [65,66]. Importantly, the engagement
of protein complexes in internalization prone membrane
domains provides an explanation for the target cell
selectivity that is difficult to imagine relying exclusively
on single adhesion molecules, which frequently are
expressed on many cells [67]. The binding of exosomes
to the surface of recipient cells is mediated by the clas-
sical adhesion molecules involved in cell–cell interac-
tions, such as integrins and ICAMs. However, othererived exosomes and release to recipient cells.
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such as TIM-binding phosphatidylserines, carbohydrate/
lectin receptors and heparan sulfateproteoglycans (HSPGs),
could be involved as well [67]. To deliver their content,
exosomes attached to a recipient cell can either fuse with
the cell membrane, directly releasing their cargo into the
cytoplasm, or get internalized by endocytic pathways. De-
pending in the phagocytic and endocytic capacity of the
recipient cells, exosomes can be internalized by clathrin-
dynamin-caveolae-dependent endocytosis, pinocytosis, or
phagocytosis [67].
Accumulating evidences from the literature support
the idea that exosomal miRNAs can act as regulators of
gene expression in distant cells. Particularly in cancer,
exosomes have multiple functions including promotion
of local and systemic processes that lead to cell growth
and dissemination, or impairment of the immune system
response. miRNAs can act either as tumor suppressors
or oncogenes (oncomiRs), depending on target genes
and cancer types. Furthermore, a particular miRNA can
exploit both tumor-suppressive and oncogenic functions
depending on the cellular context of its target genes in
different cancers [68].
Table 1 and Figure 2 epitomize most significant exoso-
mal miRNAs in cancer.
Functions of exosomal miRNAs in cancer
Exosomes have been found to act as vehicles for sup-
pressive signals and have suppressive effects on antitu-
mor immune responses [35,69]. For instance, miR-9 that
is over-expressed in many cancers is able of inhibiting
the transcription of the MHC class I gene thus prevent-
ing the recognition of tumor cells by the patient immune
system [70]. Yet, miR-222 down-regulates the expression
on tumor cell surfaces of intracellular cell adhesion
molecule 1 (ICAM-1) whose binding to lymphocyte
function-associated antigen (LFA-1) is essential for opti-
mal activation of cytotoxic T cells, which in turn mediate
tumor cell lysis [71].
In some cases, exosomal pathways might discard
tumor-suppressor miRNAs that restrict metastatic pro-
gression. For example, the let-7 miRNA family was
shown to be expressed at higher levels in exosomes de-
rived from metastatic gastric cancer cells, compared to
non-metastatic parental cells, suggesting that the exoso-
mal mechanism may be used by metastatic cells to elim-
inate miRNAs having tumor suppressive functions, thus
strengthening their aggressive behavior [72]. Another ex-
ample comes from a recent paper showing that meta-
static cells from bladder carcinoma secrete increased
levels of miRNAs with tumor-suppressor functions (e.g.
inhibition of invasion, angiogenesis, and pulmonary me-
tastasis), including miR-23b, miR-224, and miR-921.
Moreover, miRNAs, such as miR-23b, highly exocytosedfrom metastatic cells were reduced in lymph node me-
tastases compared with patient-matched primary tumors
[73]. These results suggest that exosome-mediated secre-
tion of tumor-suppressor miRNAs is selected during
tumor progression as a mechanism to coordinate activa-
tion of a metastatic cascade. An alternative hypothesis
has been proposed to justify the relative abundance of
miRNAs with predominant tumor suppressor activity in
the blood of healthy individuals. According to this hy-
pothesis, tumor-suppressor circulating miRNAs might
work as a surveillance mechanism exerting continuous
inhibition on tumor formation, complementing cancer
immune surveillance [74]. It should be noted, however,
that, in other instances, miR-23b may act as tumor pro-
moting [75].
However, most literature reports a tumor promoting
role of exosomal miRNAs, likely because tumor suppres-
sor miRNAs are downregulated in many tumors, as well
as in cancer stem cells. Many oncomiRs have been de-
scribed in the past decade. For example, IL-4 activated
macrophages have been shown to regulate invasiveness
of breast cancer cells through exosome-mediated deliv-
ery of the miR-223 highlighting a novel communication
mechanism between tumor-associated macrophages and
cancer cells [76]. miR-21 has been found up-regulated in
a wide range of solid tumors [77,78], and secreted in
plasma exosomes from patients affected by different can-
cer types, such as ovarian, lung and colon carcinomas,
pancreatic cancer and others, its presence being always
positively correlated with tumor progression and aggres-
siveness [79-82]. Up-regulation of miR-21 was shown to
promote cellular proliferation, survival, invasion and mi-
gration in different cancer cell lines [83], while its knock-
down decreased tumor cell survival in vitro and tumor
growth in vivo in a murine xenograft model, accompanied
by enhanced apoptosis [84]. Interestingly, miR-21 and -29a
secreted by tumor cells via exosomes have been shown to
bind to toll-like receptors (TRL) on immune cells, leading
to TLR-mediated NF-κB (nuclear factor kappa-light-chain-
enhancer of activated B cells) activation and secretion of
prometastatic inflammatory cytokines that may ultimately
lead to tumor growth and metastasis [85].
It is becoming clear that tumor released exosomes
contribute to both progression of primary tumors and
metastases. The central role of exosomes in tumor
promotion has been recently highlighted by the discovery
that breast cancer exosomes can perform cell-independent
miRNA biogenesis and stimulate non-tumorigenic epi-
thelial cells to form tumors, by altering their transcrip-
tome in a Dicer-dependent manner [56]. The metastatic
process involves the manipulation of the cellular micro-
environment to optimize conditions for deposition
and growth both locally and at a distance for tumor
colonization [86,87].
Table 1 Most relevant miRNAs in cancer
miRNA Tumor Main target genes Function Reference
miR-15a Multiple Myeloma BCL2, MYB, MYC, KRAS, CCND1, CDC25A,
ERBB2, TP53, PTEN, ITGA2, VEGFA,RAB21,
CADM1, DICER1
Oncogene Inhibition, Cell Cycle
Control, Inhibition of Angiogenesis
[97-100]
miR-34a Breast, Prostate, Bladder, and
Brain Cancer
BCL2, MYC, MET, MEK1, E2F3, CDK4,
CDK6, CD44
Cell Cycle Control, Apoptosis,
Senescence, Angiogenesis
[116,117,118]
let-7 family Breast, Colon, Gastric, Liver, Lung,
Prostate, Ovarian Cancer, Chronic
Myelogenous Leukemia, B Cell
Lymphoma
NF2, HRAS, KRAS, NRAS, LIN28, MYC,
DICER1, HMGA2, CASP3
Oncogene Inhibition, Cell Cycle
Control, Cancer Stem Cell
Regulation
[72,119-124,125]
miR-21 Ovarian, Lung, and Colon Carcinoma,
Pancreatic and Breast Cancer
TPM1, NFIB, PDCD4, CDKN1A, FAS,
TIMP3, SOX5, PTEN, BMPR2




miR-17-92 cluster Leukemia DICER, PTEN, E2F1, E2F2, E2F3, CDKN1A,





miR-494 Small Cell Lung Carcinoma,
Breast Cancer




miR-210 Breast Cancer, Renal, Prostate, and
Pancreatic Cancer, Lymphoma
MYC, STAT5A, HIF1A, TP53, E2F3, VEGFA,
EGFR, CDKN1A, AKT1, DICER1, PTEN,





miR-200 family Breast Cancer ZEB1, ZEB2, SIP1, CCND1, CDC25C, MYC,
MYCN, PTEN, SIRT1, VEGFA, MET,






MYC, MYCN,VEGFA, MMP9, CDH1 Metastasis, Drug Resistance,
Angiogenesis
[95,110,134,135]
miR-221/miR-222 Breast, Colorectal, Renal, Pancreatic,
and Ovarian Cancer, Melanoma,
Glioblastoma, Leukemia





miR-23b Breast, Renal, Pancreatic, Bladder,
and Prostate Cancer Thymic
Lymphoma
VHL, PTEN, FAS, NISCARI, PAK2, ATG12,
ZEB1, SRC, AKT
Cell Proliferation, Chemoresistance,
Inhibition of Invasion and
Angiogenesis
[73,75]
miR-542-3p Pancreatic, and Cervical Carcinoma,
Neuroblastoma, Colon Cancer





miR-125b Breast, and Liver Cancer LIN28B, CCND1, SOX2, MYC, CDK6, Increase Drug Resistance,
Decreased in Resistant Cells,
Inhibits Cell Proliferation
[146-149]
miR-105 Breast, Ovarian, Gastric, and Prostate
Cancer, Glioma, Hepatocellular
Carcinoma




miR-29 Breast, Lung, and Cervical Cancer,
Neuroblastoma, B Cell Chronic and
Acute Myeloid Leukemia
BACE1, DNMT3A, DNMT3B, CDC42,
CDK6, TGFB3, IFNG
Modulation of Immune
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modify distant lymph nodes to facilitate melanoma
growth and metastasis even in the local absence of
tumor cells [88]. Exosomal miRNAs derived from meta-
static adenocarcinoma cells were also involved in modu-
lation of premetastatic organ stroma cells toward
supporting tumor cell hosting. Exosomal mRNAs and
miRNAs derived from tumor cells were recovered inlymph node stroma and lung fibroblasts, and were
shown to significantly affect mRNA translation in the
target cells, exemplified by abundant recovery of exoso-
mal miR-494 and miR-542-3p, which targeted cad-
herin17 [89]. In addition to modulation of stromal cells,
recent data have also demonstrated a pivotal role for
cancer cell–derived exosomes in the organization of the
extracellular matrix (ECM). Being rich in proteases,
Figure 2 Cancer cell-secreted exosomal miRNAs contribute to the formation of the metastatic niche.
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lagens, laminin, and fibronectin, and this may have se-
vere consequences on tumor and host cell adhesion,
motility, and invasiveness [90].
Exosomal miRNAs can also participate in cancer me-
tastasis by adapting the tumor niche cells. miR-105,
which is characteristically expressed and secreted by
metastatic breast cancer cells, is a potent regulator of
migration through targeting the tight junction protein
ZO-1. In endothelial monolayers, exosome-mediated
transfer of cancer-secreted miR-105 efficiently destroys
tight junctions and the integrity of these natural barriers
against metastasis. Overexpression of miR-105 in non-
metastatic cancer cells induces metastasis and vascular
permeability in distant organs, whereas inhibition of
miR-105 in highly metastatic tumors alleviates these
effects [91]. It has been recently shown that miR-200
family members, which regulates the mesenchymal-to-
epithelial transition, within extracellular vesicles secreted
from highly metastatic tumor cells can be internalized
by weakly metastatic cells and confer the capability of
tumor growth at metastatic lesions [92,93].
The contribution of exosome in induction of angio-
genesis to promote cancer metastasis is also described.
For instance, it was shown that miRNA-enriched exo-
somes released by CD105 cancer stem cells from renal
carcinomas may modify the tumor microenvironment by
triggering angiogenesis and may promote formation of a
pre-metastatic niche [42]. Specific exosomal miRNAs,such as those of the miR-17-92 cluster, have an import-
ant role in neoplasia-to-endothelial cell communication
for regulating endothelial gene expression during tumor
angiogenesis in leukemia cells [94]. It was also shown
that tumor-secreted miR-9 encapsulated into microvesi-
cles promotes endothelial cell migration and tumour
angiogenesis participating in intercellular communica-
tion and function [95]. Moreover, exosomal angiogenic
miR-210, known to be increased in the serum of cancer
patients with malignant breast cancer, regulate the meta-
static ability of cancer cells through suppression of
specific target genes, which resulted in enhanced angio-
genesis [96]. In addition, neutral sphyngomyelinase 2
(nSMase2) was required to regulate exosomal miRNA
secretion from cancer cells and promote angiogenesis
within the tumor microenvironment as well as metasta-
sis [96]. These findings suggest that the horizontal trans-
fer of exosomal miRNAs from cancer cells can dictate
the microenviromental niche for the benefit of cancer
progression. Some studies also suggest that the micro-
environment may play a crucial role in regulating the
pathogenesis of some tumors by modulating the expres-
sion of exosomal miRNAs. Bone marrow stromal cells
modulate miR-15a, which act as putative tumor suppres-
sor in multiple myeloma cells thus facilitating the pro-
gression of this tumor [97-100].
The exosomal miRNA profiling of sera from cancer
patients versus healthy individuals has often revealed im-
portant differences in relation to tumor progression,
Falcone et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:32 Page 7 of 10highlighting a possible use of these miRNAs as disease
prognostic biomarkers [101,102]. In addition, many tu-
mors displaying drug resistance show alterations in the
expression of miRNAs. The up- or down-regulation of
miRNAs affects the expression of several target proteins
(drug targets, transporters, cell cycle- and apoptosis-
related components, key signaling pathway components
involved in drug response), determining changes in drug
sensitivity through different molecular mechanisms
[103,104]. Moreover, different studies indicate that exo-
somes act as vehicles for exchange of genetic cargo
between heterogeneous populations of tumor cells, gen-
erating a way of transmitting drug resistance [105-107].
Recently Chen and colleagues reported that exosomes
from drug resistant breast cancer cells are capable of de-
livering a subset of miRNAs (miR-100, miR-222 and
miR-30a) to sensitive cells [108]. miR-34a, detected as
both intracellular and exosomal biomarker, was recently
found also to influence prostate cancer cell response to
docetaxel by regulating anti-apoptotic BCL-2 gene [109].
In addition, the inhibition of miR-9 expression in
chemoresistant glioblastoma multiforme (GBM) cells,
by transferring to GBM cells miR-9 microvesicles-
encapsulated inhibitors, resulted in reversed expression of
the multidrug transporter and sensitized GBM cells to the
treatments [110].
Conclusions
Intensive research effort is spent to find out new cancer
diagnostic and prognostic tools. Representing a non-
invasive approach, measurement of extracellular miR-
NAs in biological fluids might prove a valuable strategy.
In addition, since dysregulation of miRNAs is fundamen-
tal to the pathogenesis of many cancers, they are attract-
ive candidates for clinical application as therapeutic
targets in both solid and hematological malignancies
[111]. Down-regulation of target oncogenes by re-
expression of tumor suppressor miRNAs, or re-expression
of tumor suppressor genes by silencing oncomiRs is ex-
pected to impair tumor growth and metastasis [112].
Noteworthy, miR-34 mimic has become the first cancer-
targeted miRNA drug (MRX34) entering Phase I clinical
trials (ClinicalTrials.govidentifier: NCT01829971) in pa-
tients with advanced hepatocellular carcinoma [113]. A
new class of drugs that specifically target miRNA path-
ways are being currently developed. They work either via
replacement of tumor suppressed miRNAs with synthetic
or viral vector encoded miRNA mimics, or via antisense-
mediated inhibition of oncogenic miRNAs. However, off-
target effects must be evaluated before such therapies can
be safely applied to the clinic. Recently, a novel system for
miRNA or antagomiR delivery applicable for both local
and systemic administration with the use of mesenchymal
stem cell microparticles was developed in in vitro models[110,114,115]. The use of miRNA-containing exosomes as
cancer prognostic biomarkers and vehicles for miRNA-
based therapy could be feasible and easily exploitable in
clinical practice, with the goal of developing a personalized
anticancer therapy.
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